Compare UK & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UK | XRTX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | China | Canada |
| Employees | 127 | N/A |
| Industry | Business Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 2.7M |
| IPO Year | N/A | 2018 |
| Metric | UK | XRTX |
|---|---|---|
| Price | $0.51 | $0.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.9K | ★ 111.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.37 |
| 52 Week High | $1.21 | $1.41 |
| Indicator | UK | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 34.02 |
| Support Level | N/A | $0.38 |
| Resistance Level | $1.17 | $0.58 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 37.70 | 14.45 |
Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, Marketing and branding services, and Other services. Marketing and branding services generate the majority of the company's revenue.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.